Renal cancer cells target of new bark-derived drug
(Medical Xpress)—Associate Professor Joe W. Ramos, PhD, a cancer biologist at the University of Hawai'i Cancer Center in collaboration with Assistant Professor William Chain, PhD, from the UH Mānoa's Chemistry Department are the first to describe the biological effects that a compound known as englerin A has on renal cancer cells.
Englerin A is a natural product found in the bark of phyllanthus engleri, a plant indigenous to east Africa. This compound was previously reported to be a potent and selective inhibitor that prevents the growth of six human renal cancer cell lines while not affecting other cancer cell types. Chain closely examined the chemical structure of englerin A and was able to effectively synthesize the compound in his lab.
"Synthesizing this compound helped us gain access to reasonable amounts of material needed for biological testing," said Chain. "Additionally, synthesizing the natural products compound from scratch enabled us to focus directly on englerin A's desired effect on human cancer cells."
With direct access to the synthesized compound Florian Sulzmaier, a graduate student in Ramos's lab, began examining the biological effects englerin A had on renal cancer cells and evaluating its impact on healthy cells.
Their findings confirmed that englerin A is a potent and selective inhibitor in the growth of human renal cancer cells. They further showed that the compound kills tumor cells and has no adverse effects on normal kidney cells. In addition, their research defines some of the biological changes caused by englerin A that precede cell death, revealing that it functions via a mechanism distinct from the current standards of care in the treatment of renal cancer.
"This discovery provides an important basis for the evaluation and validation of the compound's use as an anti-tumor drug," said Sulzmaier. "This work also provides new guidance in the search for the targets of englerin A in renal cancer cells," added Ramos.
The next step will be to identify how englerin A specifically targets renal cancer cells and to improve the compound's effectiveness. This will allow the researchers to move forward with the promise of developing a new renal anti-cancer drug.
More information: "Englerin A selectively induces necrosis in human renal cancer cells" is published in the October 22, 2012 edition of the Public Library of Science (PLOS ONE): dx.plos.org/10.137… pone.0048032
Provided by
University of Hawaii at Manoa
-
Chemical compound prevents cancer in lab
May 13, 2008 |
not rated yet |
0
-
Stanford study identifies potential anti-cancer therapy that starves cancer cells of glucose
Aug 03, 2011 |
not rated yet |
0
-
Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
Dec 21, 2007 |
not rated yet |
0
-
Cancer-seeking 'smart bombs' target kidney cancer cells
Jun 06, 2011 |
not rated yet |
0
-
Cancer-killing compound spares healthy cells
Jan 04, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be villous adenoma in colon, if there are no villi there
14 hours ago
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
American cancer society celebrates 100 years of progress
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer
4 hours ago |
not rated yet |
0
CT detects twice as many lung cancers as X-ray at initial screening exam
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer
5 hours ago |
not rated yet |
0
Research offers promising new approach to treatment of lung cancer
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer
8 hours ago |
not rated yet |
0
|
Study details genes that control whether tumors adapt or die when faced with p53 activating drugs
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Cancer
8 hours ago |
not rated yet |
0
|
Small increase in cancer risk following CT scans in childhood and adolescence
Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.
Cancer
12 hours ago |
not rated yet |
0
Slowing the aging process—only with antibiotics
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
Researchers complete largest genetic sequencing study of human disease
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
Brain can be trained in compassion, study shows
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
Having both migraines, depression may mean smaller brain
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
Novel approach for influenza vaccination shows promise in early animal testing
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...